How should I manage palpitations in a 56-year-old man with non‑obstructive coronary artery disease and a 7 % ventricular ectopic burden who has not responded to beta‑blocker therapy?

Management Approach for Symptomatic PVCs with 7% Burden After Beta-Blocker Failure

In a 56-year-old man with non-obstructive CAD and symptomatic PVCs at 7% burden who has failed beta-blocker therapy, you should escalate to either a non-dihydropyridine calcium channel blocker (verapamil or diltiazem) or proceed directly to catheter ablation, with the choice driven by patient preference and symptom severity.

Algorithmic Treatment Pathway

Step 1: Add Non-Dihydropyridine Calcium Channel Blocker

• First-line escalation after beta-blocker failure is adding or switching to verapamil or diltiazem 1
• The 2017 ACC/AHA/HRS guidelines give this a Class IIa recommendation (Level B-R) for symptomatic VA when beta-blockers are ineffective 1
• This combination approach has demonstrated efficacy in reducing ventricular ectopy burden 2
• Verapamil specifically has shown effectiveness in reducing exercise-induced ventricular ectopy from 78±59 beats to 6±8 beats in patients who failed beta-blockers alone 2

Step 2: Consider Class I Antiarrhythmic Drugs

If calcium channel blockers fail or are not tolerated:

• Propafenone or flecainide are reasonable options in structurally normal hearts 1
• However, in your patient with non-obstructive CAD, exercise caution as these agents are generally avoided due to concerns for adverse effects in any structural heart disease 1
• The guidelines note that Class I antiarrhythmics can be effective but are "generally avoided due to concerns for adverse effects" 1

Step 3: Catheter Ablation - The Definitive Option

Catheter ablation should be strongly considered at this juncture and may be preferred over further medication trials 1, 3:

When to Choose Ablation:

• Patient preference for definitive therapy over chronic medication
• Persistent symptoms despite medical therapy (your patient's current situation)
• Concern for PVC-induced cardiomyopathy (7% burden approaches the threshold where this becomes relevant)
• Younger, active patients who desire freedom from medications

Ablation Efficacy:

• Significantly superior to medical therapy in prospective randomized trials 1
• The guidelines note "far higher rate of recurrence" with metoprolol or propafenone compared to catheter ablation 1
• Most idiopathic PVCs originate from the right ventricular outflow tract (RVOT) or LV ostium, which are highly amenable to ablation 1
• Success depends on identifying the earliest site of electrical activation or pace-mapping 1

Critical Considerations for Non-Obstructive CAD Context

Risk Stratification Specific to This Patient:

1. The 7% PVC burden is clinically significant - while not meeting the traditional >10-15% threshold often cited for PVC-induced cardiomyopathy risk, symptomatic patients with burdens >5% warrant intervention 3

2. Non-obstructive CAD requires ongoing medical management regardless of PVC treatment 4, 5:

   • Continue statin therapy for plaque stabilization
   • Maintain antiplatelet therapy (typically aspirin)
   • Optimize blood pressure control
   • Address all cardiovascular risk factors aggressively

3. Ensure adequate revascularization assessment - in the context of non-obstructive CAD with symptomatic PVCs, verify that:

   • Microvascular dysfunction has been considered
   • Vasospasm has been excluded
   • Any myocardial bridging has been identified 6

Common Pitfalls to Avoid:

Pitfall #1: Assuming non-obstructive CAD means "normal heart"

• While guidelines for "structurally normal hearts" technically apply, non-obstructive CAD represents a spectrum of disease 5
• This patient requires both antiarrhythmic management AND aggressive secondary prevention 4, 5

Pitfall #2: Delaying ablation too long

• Medical therapy has modest efficacy with high recurrence rates 1
• Prolonged high PVC burden risks developing cardiomyopathy 3
• If symptoms significantly impact quality of life, earlier ablation is justified

Pitfall #3: Using Class IC antiarrhythmics without careful consideration

• Even with "non-obstructive" CAD, any coronary disease increases risk with Class IC agents
• The presence of any structural heart disease shifts the risk-benefit ratio away from these medications 1

Practical Implementation

If Choosing Medical Escalation First:

• Start verapamil 120-240mg daily or diltiazem 180-360mg daily (extended-release formulations)
• Continue beta-blocker or substitute (not add) if heart rate becomes problematic
• Reassess symptoms and repeat Holter monitoring in 4-6 weeks
• If inadequate response, proceed to ablation rather than further medication trials

If Choosing Ablation:

• Refer to experienced electrophysiology center
• Ensure 12-lead ECG of PVCs is available to predict site of origin
• Consider repeat echocardiogram to establish baseline LV function before procedure
• Ablation can be performed even if PVCs are not present during procedure using pace-mapping techniques 1

The evidence strongly favors either adding a calcium channel blocker as a bridge or proceeding directly to catheter ablation in this clinical scenario, with ablation offering superior long-term outcomes for symptom control and quality of life 1, 3.